Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015

Eur Urol. 2014 Oct;66(4):e71-2. doi: 10.1016/j.eururo.2014.06.038. Epub 2014 Jul 8.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Androgen Antagonists / therapeutic use*
  • Androstenes / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Humans
  • Male
  • Phenylthiohydantoin / analogs & derivatives*
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Receptors, Androgen / drug effects*
  • Taxoids / therapeutic use*

Substances

  • Androgen Antagonists
  • Androstenes
  • Receptors, Androgen
  • Taxoids
  • Phenylthiohydantoin